SCHEMBL6153470

SCHEMBL6153470

NC(=O)c1ccc(NC(=O)C2CCC(N)CC2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 2/20 0.56
F2 P00734 1/20 0.55
PRSS1 P07477 1/20 0.55
PRSS2 P07478 1/20 0.55
PRSS3 P35030 1/20 0.55
ST14 Q9Y5Y6 1/20 0.55
CYP2C9 P11712 1/20 0.55
HPGD P15428 1/20 0.55
KMT2A Q03164 6/20 0.54
MEN1 O00255 4/20 0.54
LMNA P02545 2/20 0.54
MAPT P10636 2/20 0.53
GAA P10253 1/20 0.53
GFER P55789 1/20 0.53
RAB9A P51151 2/20 0.52
ULK1 O75385 1/20 0.51
SMYD3 Q9H7B4 1/20 0.51
PTPN1 P18031 1/20 0.50
KDM4E B2RXH2 1/20 0.49
NPC1 O15118 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25845705 0.93 NAMPT (0.62) NAMPTCYP2C9HPGDKMT2AMEN1
SCHEMBL221545 0.88 F2 (0.70) NAMPTF2PRSS1PRSS2PRSS3
SCHEMBL28241421 0.85 PTPN1 (0.70) CYP2C9HPGDKMT2AMEN1LMNA
SCHEMBL6154809 0.83 KMT2A (0.54) NAMPTCYP2C9HPGDKMT2AMEN1
SCHEMBL6154813 0.83 KMT2A (0.54) NAMPTCYP2C9HPGDKMT2AMEN1
SCHEMBL6153241 0.83 SIRT2 (0.64) NAMPTF2CYP2C9HPGDKMT2A
SCHEMBL3093727 0.83 CYP2C9 (0.61) NAMPTCYP2C9HPGDKMT2AMEN1
SCHEMBL13972924 0.82 KMT2A (0.62) NAMPTHPGDKMT2AMEN1LMNA
SCHEMBL3211109 0.81 GAA (0.72) NAMPTHPGDKMT2AMEN1LMNA
SCHEMBL3211102 0.81 GAA (0.72) NAMPTHPGDKMT2AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050182040-A1 Benzamide derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-18 US disclosed
EP-1500643-A1 BENZAMIDE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2005-01-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182040-A1 Benzamide derivatives ROCK1, ROCK2, NHERF1 NAMPT 1121/4885F2 3162/4885PRSS1 1794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.